v3.26.3
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2026
Sep. 30, 2025
Sep. 30, 2026
Sep. 30, 2025
Operating expenses:        
Research and development (including non-cash stock-based compensation expense of $1.0 million and $0.6 million for the three months ended September 30, 2026 and 2025, respectively and $2.7 million and $1.7 million for the nine months ended September 30, 2026 and 2025, respectively) $ 23,891 $ 20,453 $ 69,939 $ 44,395
General and administrative (including non-cash stock-based compensation expense of $1.5 million and $1.2 million for the three months ended September 30, 2026 and 2025, respectively and $39.1 million and $3.5 million for the nine months ended September 30, 2026 and 2025, respectively) 6,454 4,988 53,756 15,700
Total operating expenses 30,345 25,441 123,695 60,095
Loss from operations (30,345) (25,441) (123,695) (60,095)
Other income (expense), net        
Interest income, net 3,900 2,807 9,290 8,882
Research and development tax credit 165 146 968 756
Other (income) expense, net 13 39 (67) (29)
Total other income (expense), net 4,078 2,992 10,191 9,609
Loss before income taxes (26,267) (22,449) (113,504) (50,486)
Income tax provision 127 95 898 260
Net loss (26,394) (22,544) (114,402) (50,746)
Other comprehensive income (loss), net of tax:        
Foreign currency translation adjustment 23 (3) 56 (6)
Unrealized (loss) gain on available-for-sale securities (1,224) 99 (2,033) 232
Comprehensive loss $ (27,595) $ (22,448) $ (116,379) $ (50,520)
Net loss per share, basic $ (0.49) $ (9.43) $ (3.72) $ (21.53)
Net loss per share, diluted $ (0.49) $ (9.43) $ (3.72) $ (21.53)
Weighted-average common shares outstanding, basic 53,530,550 2,389,888 30,714,936 2,357,222
Weighted-average common shares outstanding, diluted 53,530,550 2,389,888 30,714,936 2,357,222